# Residual Inflammatory Risk (RIR) in Statin-Treated Adults: NHANES Analysis

## Primary Results Summary (Updated with PI Requests)

**Date Generated:** December 26, 2025  
**Data Source:** NHANES 2005-2010, 2015-2020 (5 cycles)

---

## Study Population

| Criterion | N |
|-----------|---|
| Total fasting participants (≥20 years) | 12,896 |
| Statin users | 2,527 (19.6%) |
| Statin users with LDL-C <70 mg/dL | 577 |
| **RIR cases** (statin + LDL<70 + hs-CRP≥2) | 141 |

---

## Primary Outcome: RIR Prevalence

### Among Statin Users with LDL-C <70 mg/dL (N=577)

| Definition | Prevalence | 95% CI |
|------------|------------|--------|
| **Primary: hs-CRP ≥2 mg/L** | **21.9%** | **(15.9% - 27.9%)** |
| Sensitivity: hs-CRP ≥3 mg/L | 13.4% | (8.8% - 18.0%) |

### With stricter LDL threshold: LDL-C <55 mg/dL (N=213)

| Definition | Prevalence | 95% CI |
|------------|------------|--------|
| hs-CRP ≥2 mg/L | 26.9% | (17.0% - 36.8%) |

---

## PI REQUEST #1: 6-Group LDL × Statin Analysis

| Group | N | hs-CRP ≥2 Prevalence | SE |
|-------|---|---------------------|-----|
| LDL≤70, Statin | 582 | 22.4% | 3.0% |
| LDL≤70, No Statin | 762 | 14.5% | 2.0% |
| LDL 70-130, Statin | 1,650 | 20.1% | 1.8% |
| LDL 70-130, No Statin | 6,136 | 17.7% | 0.8% |
| LDL>130, Statin | 295 | 27.0% | 4.6% |
| LDL>130, No Statin | 3,471 | 19.8% | 1.3% |

### Mean hs-CRP by Group (mg/L)

| Group | Mean hs-CRP | SE |
|-------|-------------|-----|
| LDL≤70, Statin | 1.40 | 0.13 |
| LDL≤70, No Statin | 1.06 | 0.10 |
| LDL 70-130, Statin | 1.29 | 0.07 |
| LDL 70-130, No Statin | 1.16 | 0.04 |
| LDL>130, Statin | 1.50 | 0.17 |
| LDL>130, No Statin | 1.24 | 0.06 |

**Key findings:**
- Statin users show higher hs-CRP ≥2 prevalence than non-users within each LDL tier
- LDL≤70 without statins: 14.5% have elevated hs-CRP (supports "low LDL, high inflammation" phenotype)
- Highest inflammatory burden in LDL>130 statin group (27.0%)

---

## PI REQUEST #2: Diabetes/Prediabetes Stratification

### Glycemic Status Distribution

| Status | N | % |
|--------|---|---|
| Normal | 4,717 | 36.6% |
| Prediabetes | 5,745 | 44.5% |
| Diabetes | 2,434 | 18.9% |

### RIR Prevalence by Glycemic Status (Statin + LDL<70)

| Status | Prevalence | SE |
|--------|------------|-----|
| Normal | 15.3% | 9.3% |
| Prediabetes | 17.4% | 5.2% |
| **Diabetes** | **26.2%** | 4.8% |

### hs-CRP ≥2 Prevalence by Glycemic Status × LDL×Statin Group

| Group | Normal | Prediabetes | Diabetes |
|-------|--------|-------------|----------|
| LDL≤70, Statin | 15.3% | 17.4% | 27.2% |
| LDL≤70, No Statin | 9.3% | 20.5% | 30.0% |
| LDL 70-130, Statin | 14.2% | 17.7% | 26.2% |
| LDL 70-130, No Statin | 12.4% | 21.5% | 33.6% |
| LDL>130, Statin | 20.4% | 27.7% | 29.4% |
| LDL>130, No Statin | 13.5% | 22.4% | 31.9% |

**Key finding:** Diabetes associated with ~2× higher hs-CRP ≥2 prevalence across all LDL×statin groups.

---

## PI REQUEST #3: Sex-Stratified Analysis

### RIR Prevalence by Sex (Statin + LDL<70)

| Sex | Prevalence | SE | 95% CI |
|-----|------------|-----|--------|
| Male | 23.7% | 3.5% | 16.9-30.6% |
| Female | 19.2% | 4.5% | 10.4-28.0% |

### hs-CRP ≥2 Prevalence by Sex × LDL×Statin Group

| Group | Male | Female |
|-------|------|--------|
| LDL≤70, Statin | 23.5% | 20.9% |
| LDL≤70, No Statin | 9.7% | 18.3% |
| LDL 70-130, Statin | 18.0% | 22.5% |
| LDL 70-130, No Statin | 14.9% | 20.2% |
| LDL>130, Statin | 20.4% | 32.0% |
| LDL>130, No Statin | 17.5% | 22.0% |

### Sex-Specific Predictors of RIR

**Males (N=338):**
| Predictor | OR | 95% CI |
|-----------|-----|--------|
| BMI | 1.03 | 0.93-1.14 |
| Diabetes | 1.32 | 0.46-3.81 |
| Hypertension | 1.65 | 0.52-5.21 |

**Females (N=239):**
| Predictor | OR | 95% CI | p-value |
|-----------|-----|--------|---------|
| Age | 1.04 | 1.00-1.08 | 0.04 |
| BMI | 1.07 | 1.01-1.14 | 0.02 |
| Diabetes | 1.54 | 0.47-5.04 | NS |
| Hypertension | 1.94 | 0.50-7.45 | NS |

**Key findings:**
- Women show higher hs-CRP prevalence in non-statin groups
- In LDL>130 statin group: women 32.0% vs men 20.4%
- BMI and age are significant predictors of RIR in women but not men

---

## RIR Prevalence by Subgroups (Original Analysis)

> **Note:** Subgroup prevalence estimates are descriptive; formal interaction testing was not powered in this sample.

### By Age Group
| Age Group | RIR Prevalence | SE |
|-----------|----------------|-----|
| 20-39 | 2.7% | 2.8% |
| 40-49 | 10.5% | 5.3% |
| 50-59 | 46.8% | 9.9% |
| 60-69 | 22.7% | 5.1% |
| 70+ | 18.2% | 3.0% |

### By Race/Ethnicity
| Race/Ethnicity | RIR Prevalence | SE |
|----------------|----------------|-----|
| Mexican American | 23.5% | 6.5% |
| Other Hispanic | 29.1% | 7.3% |
| Non-Hispanic White | 20.4% | 3.9% |
| Non-Hispanic Black | 29.4% | 4.6% |
| Other/Multi-racial | 24.2% | 8.4% |

---

## RIR vs Non-RIR Characteristics

| Characteristic | No RIR | RIR | Notes |
|----------------|--------|-----|-------|
| Female (%) | 41.9% | 35.5% | — |
| Diabetes (%) | 51.1% | 64.6% | Higher in RIR |
| Hypertension (%) | 76.8% | 87.9% | Higher in RIR |
| Current Smoker (%) | 13.2% | 17.7% | Higher in RIR |
| Obesity (BMI ≥30) (%) | 45.8% | 53.5% | Higher in RIR |

---

## Predictors of RIR (Survey-Weighted Logistic Regression)

### Model 2: Demographics + Clinical Factors (N=577)

| Predictor | Odds Ratio | 95% CI | p-value |
|-----------|------------|--------|---------|
| Age (per year) | 1.00 | 0.98-1.03 | 0.98 |
| Female (vs Male) | 0.72 | 0.40-1.31 | 0.28 |
| Non-Hispanic Black (vs Mex Am) | 1.08 | 0.42-2.80 | 0.87 |
| BMI (per kg/m²) | 1.05 | 1.00-1.11 | 0.055 |
| Diabetes | 1.64 | 0.73-3.67 | 0.23 |
| Hypertension | 1.96 | 0.82-4.71 | 0.13 |
| Current Smoker | 1.96 | 0.74-5.19 | 0.17 |
| Triglycerides (per mg/dL) | 1.00 | 0.99-1.00 | 0.22 |

---

## Sensitivity Analyses

### hs-CRP Threshold Sensitivity (Statin users with LDL<70)
| hs-CRP Threshold | Prevalence | 95% CI |
|------------------|------------|--------|
| ≥1.5 mg/L | 29.6% | 23.7% - 35.5% |
| **≥2.0 mg/L** | **21.9%** | **15.9% - 27.9%** |
| ≥2.5 mg/L | 17.6% | 12.6% - 22.5% |
| ≥3.0 mg/L | 13.4% | 8.8% - 18.0% |
| ≥4.0 mg/L | 9.7% | 5.5% - 14.0% |
| ≥5.0 mg/L | 6.4% | 3.3% - 9.6% |

### LDL-C Threshold Sensitivity (with hs-CRP ≥2)
| LDL-C Threshold | N | Prevalence | 95% CI |
|-----------------|---|------------|--------|
| <55 mg/dL | 213 | 26.9% | 17.0% - 36.8% |
| <60 mg/dL | 317 | 25.7% | 17.3% - 34.1% |
| <65 mg/dL | 434 | 22.7% | 16.8% - 28.7% |
| **<70 mg/dL** | **577** | **21.9%** | **15.9% - 27.9%** |
| <80 mg/dL | 914 | 23.5% | 18.7% - 28.4% |
| <100 mg/dL | 1,605 | 20.7% | 17.4% - 24.0% |

---

## Key Findings

1. **Primary finding robust:** ~22% of statin-treated US adults achieving LDL-C <70 mg/dL have residual inflammatory risk.

2. **6-group analysis:** Statin users have higher hs-CRP prevalence than non-users within each LDL tier; 14.5% of LDL≤70 non-statin users have elevated hs-CRP (low LDL, high inflammation phenotype).

3. **Diabetes/prediabetes:** Diabetics show ~2× higher hs-CRP ≥2 prevalence across all groups.

4. **Sex differences:** Women show higher inflammatory burden in non-statin groups; BMI and age predict RIR in women but not men.

5. **Metabolic comorbidities** more common in RIR group, consistent with metabolic-inflammatory phenotype.

---

## Technical Notes

- **Data cycles:** 2005-2010, 2015-2020 (2011-2014 planned for robustness check)
- **LDL-C:** Calculated via Friedewald equation
- **Prediabetes:** HbA1c 5.7-6.4% or FPG 100-125 mg/dL
- **Diabetes:** HbA1c ≥6.5% or FPG ≥126 mg/dL or self-reported
- **Weights:** Fasting subsample weights adjusted for multi-cycle analysis
- **hs-CRP >10 mg/L excluded** to remove acute inflammation

---

## Files Generated

- `data/processed/rir_analytic_cohort.csv`
- `output/tables/rir_prevalence_results.csv`
- `output/tables/rir_prevalence_by_subgroup.csv`
- `output/tables/hscrp_by_ldl_statin_group.csv`
- `output/tables/rir_by_glycemic_status.csv`
- `output/tables/hscrp_by_sex_ldl_group.csv`

---

## Limitations

1. Cross-sectional design precludes causal inference
2. hs-CRP measured once; repeated measurements would reduce misclassification
3. Subgroup analyses are exploratory and not powered for formal comparisons
4. 2011-2014 cycles not yet incorporated
5. Statin adherence not directly measured
